Loading search results…

Scholars @ Weill Cornell Medicine

Help & supportPhase 1 prototype

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research6

Loading search results…

Browse

Scholars8,803 Publications201,993 Funding7,268 Clinical research6

FiltersClear all

Status

Recruiting3
Active, not recruiting2
Completed1

Study type

Interventional6

Phase

Phase 24
Phase 31
Phase 41

Investigator

Tracy A. Butler2
Anna Starikovsky Nordvig1
Anthony O. Ahmed1
Parag Goyal1
Sonja Blum1

Department

Neurology2
Radiology2
Medicine1
Psychiatry1

Condition

Cognitive Dysfunction6
Leukemia, Myeloid, Acute46
Prostatic Neoplasms36
Multiple Myeloma31
Breast Neoplasms26

Intervention type

Drug6
Behavioral4
Device2
Other2

Sponsor type

WCM (investigator-initiated)3
Industry2
Other academic1

Start date

Cognitive Dysfunction×Drug×Clear all

Showing 1–6 of 6 studiesSort:

RecruitingInterventional · Phase 4NCT04262206 ↗
PRagmatic EValuation of evENTs And Benefits of Lipid-lowering in oldEr Adults (PREVENTABLE)

FiltersClear all

Status

Recruiting3
Active, not recruiting2
Completed1

Study type

Interventional6

Phase

Phase 24
Phase 31
Phase 41

Investigator

Tracy A. Butler2
Anna Starikovsky Nordvig1
Anthony O. Ahmed1
Parag Goyal1
Sonja Blum1

Department

Neurology2
Radiology2
Medicine1
Psychiatry1

Condition

Cognitive Dysfunction6
Leukemia, Myeloid, Acute46
Prostatic Neoplasms36
Multiple Myeloma31
Breast Neoplasms26

Intervention type

Drug6
Behavioral4
Device2
Other2

Sponsor type

WCM (investigator-initiated)3
Industry2
Other academic1

Start date

Cognitive Dysfunction×Drug×Clear all

Showing 1–6 of 6 studiesSort:

RecruitingInterventional · Phase 4NCT04262206 ↗
PRagmatic EValuation of evENTs And Benefits of Lipid-lowering in oldEr Adults (PREVENTABLE)

Show all 50

Show fewer

Carcinoma, Non-Small-Cell Lung23
Colitis, Ulcerative23
Myelodysplastic Syndromes23
Neoplasms23
Recurrence22
Neoplasm Metastasis19
COVID-1918
Crohn Disease18
Obesity17
Colorectal Neoplasms16
Hematologic Neoplasms14
Heart Failure13
Non-alcoholic Fatty Liver Disease13
Overweight13
Parkinson Disease13
HIV Infections12
Primary Myelofibrosis11
Idiopathic Pulmonary Fibrosis10
Leukemia, Lymphocytic, Chronic, B-Cell10
Leukemia, Myelomonocytic, Chronic10
Lymphoma, Follicular10
Lymphoma, Non-Hodgkin10
Myeloproliferative Disorders10
Cardiovascular Diseases9
Lung Diseases, Interstitial9
Atrial Fibrillation8
Burkitt Lymphoma8
Inflammatory Bowel Diseases8
Leukemia8
Lung Neoplasms8
Lymphoma, Large B-Cell, Diffuse8
Pulmonary Arterial Hypertension8
Urinary Bladder Neoplasms8
Alzheimer Disease7
Stomach Neoplasms7
Adenocarcinoma Of Esophagus6
Anemia6
Carcinoma, Renal Cell6
Carcinoma, Transitional Cell6
Colonic Neoplasms6
Fibrosis6
Hypertension6
Hypertension, Pulmonary6
Lymphoma, Mantle-Cell6
Ovarian Neoplasms6

Parag GoyalPI

Intervention: Drug: Atorvastatin 40 Mg Oral Tablet · Drug: Placebo oral tablet
Dates: Sep 2020 – Dec 2026 (est.)
Sponsor: Duke University

Cognitive Impairment, MildDementiaCardiovascular Diseases

Active, not recruitingInterventional · Phase 2NCT06223360 ↗

A Seamless Phase 2A-Phase 2B Randomized Double-Blind Placebo- Controlled Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)

Anna Starikovsky NordvigPI

Intervention: Drug: Low Dose Benfotiamine · Drug: High Dose Benfotiamine · Drug: Placebo
Dates: Mar 2024 – Dec 2027 (est.)
Sponsor: Winifred Masterson Burke Medical Research

Alzheimer Disease

RecruitingInterventional · Phase 2NCT06502964 ↗

Double-Blind, Placebo-Controlled Study of ALTO-101 in Patients With Schizophrenia and Cognitive Impairment

Anthony O. AhmedPI

Intervention: Drug: ALTO-101 · Device: ALTO-101 Transdermal Delivery System · Drug: Placebo · Device: Placebo Transdermal Delivery System
Dates: Jun 2024 – Feb 2026 (est.)
Sponsor: Alto Neuroscience

SchizophreniaCognitive Impairment

Active, not recruitingInterventional · Phase 3NCT07169578 ↗

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease (MCI to Mild Dementia Due to AD)

Sonja BlumPI

Intervention: Drug: Trontinemab · Other: Placebo
Dates: Sep 2025 – Feb 2028 (est.)
Sponsor: F. Hoffman La-Roche Ltd

Alzheimers Disease

RecruitingInterventional · Phase 2NCT07553338 ↗

Safety Assessment of Leronlimab and Its Effect on Neuroinflammation Targets in Alzheimer's Disease

Tracy A. ButlerPI

Intervention: Drug: Leronlimab (700mg)
Dates: Apr 2026 – Nov 2027 (est.)
Sponsor: Weill Medical College of Cornell University

Mild Cognitive Impairment (MCI) Due to Alzheimer's DiseaseAlzheimer's Disease

CompletedInterventional · Phase 2NCT03649724 ↗

The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's

Tracy A. ButlerPI

Intervention: Drug: Placebo · Drug: Eligard 22.5Mg Suspension for Injection
Dates: Nov 2020 – Jul 2026
Sponsor: Weill Medical College of Cornell University

Alzheimer DiseaseMild Cognitive Impairment

Browse

Browse

PRagmatic EValuation of evENTs And Benefits of Lipid-lowering in oldEr Adults (PREVENTABLE)

PRagmatic EValuation of evENTs And Benefits of Lipid-lowering in oldEr Adults (PREVENTABLE)

A Seamless Phase 2A-Phase 2B Randomized Double-Blind Placebo- Controlled Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)

Double-Blind, Placebo-Controlled Study of ALTO-101 in Patients With Schizophrenia and Cognitive Impairment

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease (MCI to Mild Dementia Due to AD)

Safety Assessment of Leronlimab and Its Effect on Neuroinflammation Targets in Alzheimer's Disease

The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's